Federal grant · project grant (b)
We Have Initiated a Pipeline for Developing Products for HLB Treatment, HLB Prevention, and Acp Control and Propose to Expand It Under This Cap. Toward This Goal, We Have Assembled an Entrepreneurial Team of Scientists With Expertise in Disease Biology and Therapy, Regulatory Consultants With Experience in Obtaining Product Approval From Federal Agencies, and Business Experts With a Track Record in Commercialization of Agricultural Products. Our Team Will Register a Product for HLB Treatment in 3 Years. We Will Be Able to Register a Transgenic Product for HLB Prevention in 7 Years First by Collecting Efficacy, Toxicity, and Safety Data in 5 Years (2 Years After This Pilot Cap) and Then by Collecting Citrus Health and Fruit Quality Data in Next 2 Years. in Addition, We Will Create a Knowledge Base for Researchers, Which Will Describe Our Concept and Its Application in Therapy of HLB and Other Plant Diseases. Finally, Our Cap Will Include a Component on Education and Outreach That Will Involve Two Important Functions: Training of Students, Technicians, and Extension Professionals on the Knowledge Base and Holding Onsite and Online Meetings/workshops to Communicate to the Growers and Stakeholders the Scope, Deliverables, and Impact of Our Cap.following the Recommendation of the Reviewers, the Objectives Have Been Revised as Constrained by the Reduced Total Budget (from 11.8M to 4.75M) and Project Duration (3 Years Instead of 5). However, the Project Theme Remains the Same, I.e., to Demonstrate That Enhancement of Citrus Innate Immunity via Delivery of the Citrus Derived Helix-turn-helix (HTH) Peptides and Protein Chimeras Leads to Efficacious HLB Therapy. the Focus Is on Completing and Publishing the Ongoing Greenhouse and Field Studies to Unequivocally Show That the Citrus Derived Helix-turn-helix (HTH) Peptides and Protein Chimeras (i) Clear Candidatus Liberibacter Asiaticus (clas), (II) Suppress HLB Symptoms, (III) Block Clas Transmission by Asian Citrus Psyllid (acp), (IV) Show No Human and Plant Toxicity, (V) Augment Citrus Innate Immunity During Clas Infection, and (VI) Maintain Homeostasis of Microbiome Beneficial to Citrus. We Will Also Concurrently
Committed
$4.8 Million
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.